US sales in Q1 is estimated at USD 270-276 million from USD 285 million (QoQ), due to pricing pressure in drugs such as Valcyte & Vidaza generic. Also, there may be some pressure in US due to market share loss in Sumatriptan auto-injector and Dacogen generic.
first published: Jul 25, 2016 12:00 pm
A collection of the most-viewed Moneycontrol videos.
Live: Will Nifty extend gains to third day and reclaim record highs? | Opening Bell
Decoding Small-Caps - Opportunities, Risks, and the Right Way to Invest
Live: Broad-based buying lifts D-Street for 2nd day, Nifty above 26,100 | Closing Bell
In your 20s? Quick hacks to turn your money mess into money moves
